OPSMILL
28.5.2024 12:01:28 CEST | Business Wire | Press release
OpsMill, a pioneer in infrastructure and network automation, today announced the beta release of its open source Infrahub platform. Infrahub unifies previously disparate automation capabilities into a single platform, enabling IT teams to transform all their data center, cloud, network, and security infrastructure operations with scalable and consumable automation.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240528726475/en/
Infrahub brings the worlds of infrastructure-as-code and infrastructure management together in a single platform (Graphic: Business Wire)
“I’ve spent years building automation systems for infrastructure and network management across a variety of organizations. At every stop, I encountered the same challenges: Managing network and cloud infrastructure required the use of a confusing, cumbersome, costly mix of solutions. These tools were always hampered by serious technical limitations, such as inflexible data models,” said Damien Garros, CEO and co-Founder, OpsMill. “With the release of Infrahub’s open beta, we’ve drawn on years of experience to solve those challenges. This is the first platform that unites the GitOps Infrastructure-as-Code approach with an extensible structured data model. By combining these two approaches, Infrahub frees infrastructure and automation teams from having to integrate and maintain a fragile set of tools. Instead, they can focus on driving innovation through better automation.”
Infrastructure automation has suffered from an unhelpful divide between GitOps and traditional infrastructure management approaches that prevents teams from gaining the critical advantages and best practices of both approaches. GitOps, an automation approach used by many software development teams, offers version control and continuous integration (CI) validation, which are critical for maintaining an accurate data model while scaling automation use. However, GitOps doesn’t offer a structured data model that most easily represents IT infrastructure components and their many inter-linkages. Traditional infrastructure management approaches offer infrastructure-friendly structured databases, but don’t include version control or CI, and are constrained by fixed data models that limit their flexibility.
Infrahub unifies the best of both worlds in a single platform, including the following key capabilities:
- Extensible Graph Database: Infrahub overcomes the limitations of source-of-truth databases that come with fixed schemas. It is built on an extensible, knowledge-graph database that is ideal for representing and querying the many interrelationships between infrastructure components. Infrahub’s flexible data model means that it can scale across data centers, clouds, networks, and security infrastructure and use cases.
- Version Control: Infrahub makes versioning possible for your entire data model and all the data populated into that model. This means that multiple members of your team can, in parallel, create a branch of the entire infrastructure database, update an infrastructure component in the database in order to generate configuration files for a network change, then merge the updates back into the database. Native versioning of a centralized and extensible infrastructure database is a key innovation of Infrahub.
- Artifact Rendering: Infrahub doesn’t leave you alone in managing the generation of artifacts such as configuration files or reporting data files. It includes native artifact rendering as a native platform capability.
- Continuous Integration (CI): Infrahub has built in the process for performing CI validations to ensure quality control over configuration and data changes.
“As someone who has engineered large backbone networks and helped build a company that relied on extensive network and cloud infrastructure, I’ve seen firsthand how much organizations struggle with scalable and maintainable automation,” said Raphael Maunier, COO and co-Founder, OpsMill. “Infrastructure teams often need their own dev teams just to gather data and build infrastructure, leading to high maintenance costs and slowed innovation. OpsMill was founded to change this. Infrahub provides all the key elements for scalable infrastructure and network automation success, allowing teams to focus on innovation instead of maintaining custom software.”
The open beta version of Infrahub is available now. Visit GitHub to get started today.
About OpsMill
OpsMill is the infrastructure automation platform company, bringing the best practices and features of the industry’s leading automation approaches together in a single, scalable, and extensible platform so that infrastructure, cloud, network, and security teams can focus on innovation rather than integrating toolsets. Infrahub by OpsMill is the industry’s leading open-source integrated infrastructure automation platform. OpsMill is backed by Serena Capital, Partech, OVNI Capital, Kima Ventures and Better Angle. For more information, visit OpsMill.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240528726475/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
